Atossa Therapeutics Inc. (ATOS) is primed for evolution with the beta value of 1.98 – Invest Chronicle

Atossa Therapeutics Inc. (ATOS) is primed for evolution with the beta value of 1.98

For the readers interested in the stock health of Atossa Therapeutics Inc. (ATOS). It is currently valued at $1.50. When the transactions were called off in the previous session, Stock hit the highs of $1.60, after setting-off with the price of $1.51. Company’s stock value dipped to $1.50 during the trading on the day. When the trading was stopped its value was $1.54.Recently in News on December 22, 2021, Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden. Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. You can read further details here

Atossa Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.8000 on 01/04/22, with the lowest value was $1.4500 for the same time period, recorded on 01/10/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Atossa Therapeutics Inc. (ATOS) full year performance was 46.67%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Atossa Therapeutics Inc. shares are logging -84.64% during the 52-week period from high price, and 49.01% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $9.80.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1013008 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Atossa Therapeutics Inc. (ATOS) recorded performance in the market was -3.75%, having the revenues showcasing -49.17% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 195.00M, as it employees total of 4 workers.

Atossa Therapeutics Inc. (ATOS) in the eye of market guru’s

During the last month, 0 analysts gave the Atossa Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.6928, with a change in the price was noted -1.66. In a similar fashion, Atossa Therapeutics Inc. posted a movement of -51.88% for the period of last 100 days, recording 4,116,087 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ATOS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

>> 7 Top Picks for the Post-Pandemic Economy << 

Atossa Therapeutics Inc. (ATOS): Stocks Technical analysis and Trends

Raw Stochastic average of Atossa Therapeutics Inc. in the period of last 50 days is set at 6.17%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 15.79%. In the last 20 days, the company’s Stochastic %K was 9.85% and its Stochastic %D was recorded 8.87%.

If we look into the earlier routines of Atossa Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -3.75%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -75.75%, alongside a boost of 46.67% for the period of the last 12 months. The shares increased approximately by -10.47% in the 7-day charts and went up by -23.38% in the period of the last 30 days. Common stock shares were lifted by -49.17% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts